Other options that can be considered for refractory hypoglycemia include somatostatin analogs, such as octreotide (14) and lanreotide (15), although the efficacy is often less predictable, and they have also been reported to worsen hypoglycemia paradoxically by suppressing the release of glucagon and growth hormone. This evidence concerns the gene GCG and Hypoglycemia.